Fate Therapeutics, Inc. (FATE) is a publicly traded Healthcare sector company. As of May 20, 2026, FATE trades at $1.93 with a market cap of $201.65M and a P/E ratio of -1.69. FATE moved +1.85% today. Year to date, FATE is +91.61%; over the trailing twelve months it is +54.92%. Its 52-week range spans $0.66 to $3.80. Analyst consensus is buy with an average price target of $4.46. Rallies surfaces FATE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes FATE SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $1.93 |
| Market Cap | $201.65M |
| P/E Ratio | -1.69 |
| EPS | $-1.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.80 |
| 52-Week Low | $0.66 |
| Volume | 1.46M |
| Avg Volume | 0 |
| Revenue (TTM) | $6.32M |
| Net Income | $-129.91M |
| Gross Margin | 0.00% |
7 analysts cover FATE: 0 strong buy, 3 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $4.46.